BioSpace News Archive

The healthcare system is innovating to address the pain points the pandemic revealed. Specifically, it is becoming more proactive, preventative and personalized.

Fauci, a longtime infectious disease expert, said COVID-19 is the stuff of nightmares in the way it has quickly spread across the globe, infected millions of people and contributed to the deaths of more than 408,000 people.

CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it intends to offer and sell, subject to market and other conditions, up to $100.0 million of shares of its common stock in an underwritten public offering.

Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.2 million and a loss per share of $0.14 for the fiscal quarter ended April 30, 2020.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, today announced positive topline results of its Phase 2a trial evaluating safety and efficacy of OPT-302 administered with Eylea®

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced it has commenced a public offering of shares of its common stock.

Alphamab Oncology (stock code: 9966 HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Jiangsu Alphamab”), a wholly-owned subsidiary of the Company, has entered a partnership agreement with Institut Pasteur of Shanghai, Chinese Academy of Sciences (“Institut Pasteur Shanghai”)

Ardelyx, Inc. announced that on June 8, 2020, the compensation committee of the Company’s Board of Directors granted a non-qualified stock option award to purchase 195,017 shares of its common stock and a restricted stock unit award for 10,000 shares in connection with the commencement of employment of its new Chief Financial Officer, Justin Renz

AVITA Medical Limited ACN 058 466 523 (Company) is pleased to confirm that the general meeting to consider a resolution to approve the proposed scheme of arrangement to effect a redomiciliation of the Company and its subsidiaries from Australia to the United States of America (Scheme Meeting) is being held by way of live webcast at 9.00am (AEST) on Monday, 15 June 2020 (being 7.00pm (EDT) on Sunday, 14 June 2020).